Artificial vein thrombosis in dialysis patients. Thrombosis of cardiac prosthetic devices, implants and grafts, initial encounter
Conditions
Interventions
Intervention group: In the intervention group, after implanting an artificial dialysis vessel to the patient, 2.5 daily. mg rivaroxaban.
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Dependence on hemodialysis or the need for hemodialysis in the near future Installing a new artificial vein for dialysis
Exclusion criteria
Exclusion criteria: Recent major bleeding (within the last 6 months) that is defined as follows: bleeding requiring transfusion, bleeding in a high-risk area (retroperitoneal or intracranial), bleeding that caused a decrease in body volume or hospitalization, or bleeding that caused Hg drop is more than 2 gr/dl. Inability to take oral medication Anticoagulant use for another reason Life expectancy of less than two months or waiting for recovery of renal failureOpen in
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thrombosis rate of artificial vein in one, three and six months after implantation of artificial dialysis vessel. Timepoint: in one, three and six months after implantation of artificial dialysis vessel. Method of measurement: Occurrence of thrombosis in an artificial vessel. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJamal jalili shahri
Mashhad University of Medical Sciences
Outcome results
None listed